Cyclophilin inhibitors in hepatitis C viral infection

Bibliography

• Hepatitis C – global prevalence (update). Wkly Epidemiol. Rec. (2000) 75(3):18-19.
   PubMedGoogle Scholar
• ALTER HJ: HCV natural history: the retrospective and prospective in perspective. J. Hepatol. (2005) 43(4):550-552.
   PubMed Web of Science ®Google Scholar
• ZOULIM F, CHEVALLIER M, MAYNARD M, TREPO C: Clinical consequences of hepatitis C virus infection. Rev. Med. Virol. (2003) 13(1):57-68.
   PubMed Web of Science ®Google Scholar
• HUGHES CA, SHAFRAN SD: Chronic hepatitis C virus management: 2000 – 2005 update. Ann. Pharmacother. (2006) 40(1):74-82.
   PubMed Web of Science ®Google Scholar
• FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347(13):975-982.
   PubMed Web of Science ®Google Scholar
• MANNS MP, MCHUTCHISON JG, GORDON SC et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358(9286):958-965.
   PubMed Web of Science ®Google Scholar
• LINDENBACH BD, RICE CM: Unravelling hepatitis C virus replication from genome to function. Nature (2005) 436(7053):933-938.
   PubMed Web of Science ®Google Scholar
• PENIN F, DUBUISSON J, REY FA, MORADPOUR D, PAWLOTSKY JM: Structural biology of hepatitis C virus. Hepatology (2004) 39(1):5-19.
   PubMed Web of Science ®Google Scholar
• REESINK HW, ZEUZEM S, WEEGINK CJ et al.: Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 131(4):997-1002.
   PubMed Web of Science ®Google Scholar
• KIEFER T, SARRAZIN C, MILLER J et al.: Combination of telaprevir (VX-950) and PEG-IFN-α suppressed both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day Phase IB study. Hepatology (2006) 44:A222 (Abstract 92).
   Google Scholar
• ZEUZEM S, SARRAZIN C, WAGNER F: Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype 1 peg-intron non-responders: Phase Ib results. Hepatology (2005) 42:A276 (Abstract 201).
   Web of Science ®Google Scholar
• O'BRIEN C, GODOFSKY E, RODRIQUEZ-TORRES M: Randomized trial of valopicitabine (NM283) alone or with peg-interferon vs retreatment with peg-interferon plus ribavirin in hepatitis C patients with previous non-response PEGIFN/RBV: first interim results. Hepatology (2005) 42:A234 (Abstract 95).
   Google Scholar
• LAWITZ E, NGUYEN T, YOUNES Z et al.: Valopicitabine (NM283) plus PEG-interferon in treatment-naive hepatitis C patients with HCV genotype-1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatology (2006) 44:A223 (Abstract 93).
   Google Scholar
• VILLANO S, HOWE A, RAIBLE D et al.: Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. Hepatology (2006) 44:A607 (Abstract 1127).
   Web of Science ®Google Scholar
• ROBERTS S, COOKSLEY G, DORE G et al.: Results of a Phase IB multiple dose study of R1626 a novel nucleoside analog targetting HCV polymerase in chronic HCV genotype 1 patients. Hepatology (2006) 44:A692 (Abstract LB2).
   Google Scholar
• KOLETSKY AJ, HARDING MW, HANDSCHUMACHER RE: Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J. Immunol. (1986) 137(3):1054-1059.
   PubMed Web of Science ®Google Scholar
• EDLICH F, FISCHER G: Pharmacological targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases. Handb. Exp. Pharmacol. (2006) (172):359-404.
   PubMedGoogle Scholar
• RYFFEL B, WOERLY G, GREINER B et al.: Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology (1991) 72(3):399-404.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA M, SAKAMOTO N, TANABE Y et al.: Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology (2005) 129(3):1031-1041.
   PubMed Web of Science ®Google Scholar
• WATASHI K, ISHII N, HIJIKATA M et al.: Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell (2005) 19(1):111-122.
   PubMed Web of Science ®Google Scholar
• WATASHI K, HIJIKATA M, HOSAKA M, YAMAJI M, SHIMOTOHNO K: Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology (2003) 38(5):1282-1288.
   PubMed Web of Science ®Google Scholar
• FIRPI RJ, ZHU H, MORELLI G et al.: Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplant. (2006) 12(1):51-57.
   PubMed Web of Science ®Google Scholar
• INOUE K, SEKIYAMA K, YAMADA M et al.: Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. (2003) 38(6):567-572.
   PubMed Web of Science ®Google Scholar
• MA S, BOERNER JE, TIONGYIP C et al.: NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with α interferon. Antimicrob. Agents. Chemother. (2006) 50(9):2976-2982.
   PubMed Web of Science ®Google Scholar
• PAESHUYSE J, KAUL A, DE CLERCQ E et al.: The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 43(4):761-770.
   PubMed Web of Science ®Google Scholar
• FLISIAK R, HORBAN A, KIERKUS J et al.: The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naive HIV/HCV co-infected subjects. 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA (27 – 31 October 2006).
   Google Scholar
• GOTHEL SF, MARAHIEL MA: Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol. Life Sci. (1999) 55(3):423-436.
   PubMed Web of Science ®Google Scholar
• STEPKOWSKI SM: Molecular targets for existing and novel immunosuppressive drugs. Expert Rev. Mol. Med. (2000) 2000:1-23.
   PubMedGoogle Scholar
• CASTRO AP, CARVALHO TM, MOUSSATCHE N, DAMASO CR: Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles. J. Virol. (2003) 77(16):9052-9068.
   PubMed Web of Science ®Google Scholar
• FRANKE EK, YUAN HE, LUBAN J: Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 372(6504):359-362.
   PubMed Web of Science ®Google Scholar
• LUBAN J: Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. (2007) 81(3):1054-1061.
   PubMed Web of Science ®Google Scholar
• TOWERS GJ, HATZIIOANNOU T, COWAN S et al.: Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. (2003) 9(9):1138-1143.
   PubMed Web of Science ®Google Scholar
• YURCHENKO V, CONSTANT S, BUKRINSKY M: Dealing with the family: CD147 interactions with cyclophilins. Immunology (2006) 117(3):301-309.
   PubMed Web of Science ®Google Scholar
• YAO Q, LI M, YANG H et al.: Roles of cyclophilins in cancers and other organ systems. World J. Surg. (2005) 29(3):276-280.
   PubMed Web of Science ®Google Scholar
• ALLAIN F, DURIEUX S, DENYS A, CARPENTIER M, SPIK G: Cyclophilin B binding to platelets supports calcium-dependent adhesion to collagen. Blood (1999) 94(3):976-983.
   PubMed Web of Science ®Google Scholar
• ALLAIN F, BOUTILLON C, MARILLER C, SPIK G: Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies. J. Immunol. Methods (1995) 178(1):113-120.
   PubMed Web of Science ®Google Scholar
• KONG W, LI S, LONGAKER MT, LORENZ HP: Cyclophilin C-associated protein is up-regulated during wound healing. J. Cell Physiol. (2007) 210(1):153-160.
   PubMed Web of Science ®Google Scholar
• WALDMEIER PC, ZIMMERMANN K, QIAN T, TINTELNOT-BLOMLEY M, LEMASTERS JJ: Cyclophilin D as a drug target. Curr. Med. Chem. (2003) 10(16):1485-1506.
   PubMed Web of Science ®Google Scholar
• RICE CM, YOU S: Treating hepatitis C: can you teach old dogs new tricks? Hepatology (2005) 42(6):1455-1458.
   PubMedGoogle Scholar
• WATASHI K, SHIMOTOHNO K: Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev. Med. Virol. (2007) 17(4):245-52.
   PubMed Web of Science ®Google Scholar
• WATASHI K, SHIMOTOHNO K: Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target. J. Drug Target Insights (2007) 1:9-18.
   Google Scholar
• ISHII N, WATASHI K, HISHIKI T et al.: Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. (2006) 80(9):4510-4520.
   PubMed Web of Science ®Google Scholar
• MIYAMOTO M, KATO T, DATE T, MIZOKAMI M, WAKITA T: Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1). Intervirology (2006) 49(1-2):37-43.
   PubMed Web of Science ®Google Scholar
• ROBIDA JM, NELSON HB, LIU Z, TANG H: Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J. Virol. (2007) 81(11):5829-5840.
   PubMed Web of Science ®Google Scholar
• TERAOKA S, MISHIRO S, EBIHARA K et al.: Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus. Transplant. Proc. (1988) 20(3 Suppl. 3):868-876.
   PubMed Web of Science ®Google Scholar
• ROSENWIRTH B, BILLICH A, DATEMA R et al.: Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. (1994) 38(8):1763-1772.
   PubMed Web of Science ®Google Scholar
• GOTO K, WATASHI K, MURATA T et al.: Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun. (2006) 343(3):879-884.
   PubMed Web of Science ®Google Scholar
• LIN K, BOERNER J, COOREMAN M: NIM811, a cyclophilin inhibitor targetting host-viral interaction, significantly enhances the antiviral activity of HCV polymerase inhibitors and reduces the emergence of resistance in vitro. First International Workshop on Hepatitis C Resistance and New Compounds, Boston, MA, USA (25 – 26 October 2006).
   Google Scholar
• HANSSON MJ, MATTIASSON G, MANSSON R et al.: The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J. Bioenerg. Biomembr. (2004) 36(4):407-413.
   PubMed Web of Science ®Google Scholar
• CHATTERJI U, BOBARDT MD, STANFIELD R et al.: Naturally occuring capsid substitutions render HIV-1 cyclophilin a independent in human cells and trim-cyclophilin resistant in owl monkey cells. J. Biol. Chem. (2005) 280(48):40293-40300.
   PubMed Web of Science ®Google Scholar
• PAESHUYSE J, COELMONT L, KAUL A et al.: The cyclophilin inhibitor Debio-025 is a potent inhibitor of hepatitis C virus replication in vitro. 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA (27 – 31 October 2006).
   Google Scholar
• COELMONT L, PAESHUYSE J, KAPTEIN S et al.: The cyclophilin Debio-025, a potent inhibitor of hepatitis C virus replication in vitro has a unique resistance profile. 1st International Workshop on Hepatitis C Resistance and New Compounds. Boston, MA, USA (October 25 – 26 2006).
   Google Scholar
• INOUE K, UMEHARA T, RUEGG UT et al.: Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology (2007) 45(4):921-928.
   PubMed Web of Science ®Google Scholar
• HOUCK D, HOPKINS S: Preclinical evaluation of SCY-635, a cyclophilin inhibitor with potent anti-HCV activity. Hepatology (2006) 44:A534 (Abstract 934).
   Google Scholar
• NEYTS J: Selective inhibitors of hepatitis C virus replication. Antiviral. Res. (2006) 71(1-2):363-371.
   PubMed Web of Science ®Google Scholar
• COTLER SJ, MORRISSEY MJ, WILEY TE, LAYDEN TJ, JENSEN DM: A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J. Clin. Gastroenterol. (2003) 36(4):352-355.
   PubMed Web of Science ®Google Scholar
• INOUE K, YOSHIBA M: Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant. Proc. (2005) 37(2):1233-1234.
   PubMed Web of Science ®Google Scholar
• BERENGUER M, AGUILERA V, PRIETO M et al.: Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transplant. (2006) 12(5):762-767.
   PubMed Web of Science ®Google Scholar
• HILGARD P, KAHRAMAN A, LEHMANN N et al.: Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J. Gastroenterol. (2006) 12(5):697-702.
   PubMed Web of Science ®Google Scholar
• VILLAMIL F, LEVY G, GRAZI GL et al.: Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant. Proc. (2006) 38(9):2964-2967.
   PubMed Web of Science ®Google Scholar
• MCHUTCHISON JG, ZEUZEM S, BENHAMOU Y et al.: Interim antiviral and safety data with albumin interferon α-2B combined with ribavirin in a Phase IIB study conducted in a genotype 1, IFN-naive, chronic hepatitis C population. Hepatology (2006) 44:A614 (Abstract 1141).
   Google Scholar
• JACOBSON I, POCKROS P, BENHAMOU Y et al.: Impact of taribavirin and ribavirin exposure on efficacy and anemia rates when combined with pegylated interferon α-2B in the treatment of chronic HCV. Hepatology (2006) 44:A610 (Abstract 1133).
   Web of Science ®Google Scholar